NCT06152731RecruitingPhase 2
HRD Tests for Ovarian cancER
Source: ClinicalTrials.gov · Last updated 17 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy. To determine HRD status, 2 separate tests will be performed in the study: 1. Giscar assay : developed by the sponsor 2. myChoice assay If one or two tests identifies a HRD status : a PARP inhibitor treatment may be initiated according to current recommendations
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- First submitted
- 22 Nov 2023
- Start date
- 15 Feb 2024
- Primary completion date
- Jun 2031
- Lead sponsor
- Centre Francois Baclesse
- Diseases
- Ovarian cancer
- NCT number
- NCT06152731
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 88
- From 15 Feb 2024 to the primary completion date, Jun 2031
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Non epithelial or borderline ovarian cancer
- Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
Other
- Exclusive palliative setting
- Patient deprived of liberty or placed under the authority of a tutor
Who the study is looking for
- Patient aged 18-year or more
- Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
- Newly diagnosed advanced (International Federation of Gynecology and Obstetrics \[FIGO\] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy
- Tumor tissue must be available for HRD analyses (FFPE tissue block) and
- Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
- With sufficient tumour surface area (\> 25 mm²), with a final cellularity of at least 20%
- Patient affiliated to an appropriate social security system
- Patient signed consent form before any trial related activities
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Amiens Coordinator of this site? Confirm its status | Amiens | France | Not yet recruiting |
| Centre François Baclesse Coordinator of this site? Confirm its status | Caen | France | Recruiting |
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Recruiting |
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.